Credo Technology Group Holding Ltd vs Charles River Laboratories Intl. Inc — how do they compare? Credo Technology Group Holding Ltd trades at $216.38 (market cap $39.82B), while Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B). The key difference: Credo Technology Group Holding Ltd is far larger — about 2.8× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Charles River Laboratories Intl. Inc for 33 Days on average.
| CRDO | CRL | |
|---|---|---|
Market Cap | $39.82B | $14.23B |
Volume | 9,451,558 | 1,176,885 |
Sector | Technology | Health |
52-Week High | $302.52 | $310.77 |
52-Week Low | $87.81 | $149.93 |
Typical Hold Time | 22 Days | 33 Days |
Enterprise Value | $39.08B | $17.06B |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $213.95, down 2.75% today but maintains strong technical support near $214. The company demonstrates exceptional fundamental performance with 114.7% YoY revenue growth and 33.83% net margins. Recent earnings beats and bullish analyst consensus at 87.5% buy ratings support the positive outlook. Technical indicators show bullish moving averages while oscillators remain neutral, with key support at $204 and resistance at $222.
CRDO presents compelling growth potential driven by AI infrastructure demand, with consensus price target of $267.33 offering 25% upside. Risks include premium valuation (P/E 74.6) and customer concentration, but strong cash flow generation and expanding optical business provide fundamental support. The stock's recent pullback may offer entry opportunity for growth investors.
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →